KWON YOUNG Form 4 July 16, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB 323

OMB APPROVAL

Number:

3235-0287 January 31,

2005

0.5

Expires: Sanda Expires:

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction 30(h) of the Investment Comp

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person **
KWON YOUNG

2. Issuer Name **and** Ticker or Trading

Symbol

MOMENTA

PHARMACEUTICALS INC

[MNTA]

(Last) (First) (Middle)

3. Date of Earliest Transaction

(Month/Day/Year) 07/12/2018

5. Relationship of Reporting Person(s) to

Issuer

below)

(Check all applicable)

____ Director _____ 10% Owner ____ X__ Officer (give title ____ Other (specify

SVP, Corporate Development

C/O MOMENTA

PHARMACEUTICALS, INC., 301 BINNEY STREET

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

_X_Form filed by One Reporting Person ___ Form filed by More than One Reporting

Person

CAMBRIDGE, MA 02142

(City)	(State)	(Zip) Tabl	le I - Non-D	Perivative S	Securi	ities Acqu	ired, Disposed of	f, or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securit on(A) or Di (Instr. 3,	sposed	d of (D)	5. Amount of Securities Ownership Beneficially Form: Direct Owned (D) or Following Indirect (I) Reported (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)	
Common Stock	07/12/2018		M <u>(1)</u>	11,000	A	\$ 13.26	148,623	D	
Common Stock	07/12/2018		S <u>(1)</u>	11,000	D	\$ 25.4 (2)	137,623	D	
Common Stock	07/12/2018		M <u>(1)</u>	5,500	A	\$ 15.44	143,123	D	
Common Stock	07/12/2018		S(1)	5,500	D	\$ 25.54	137,623	D	

Edgar Filing: KWON YOUNG - Form 4

					(2)		
Common Stock	07/12/2018	M <u>(1)</u>	6,000	A	\$ 12.58	143,623	D
Common Stock	07/12/2018	S <u>(1)</u>	6,000	D	\$ 25.41 (2)	137,623	D
Common Stock	07/12/2018	M(1)	6,000	A	\$ 17.96	143,623	D
Common Stock	07/12/2018	S <u>(1)</u>	6,000	D	\$ 25.41 (2)	137,623	D
Common Stock	07/12/2018	M <u>(1)</u>	4,000	A	\$ 13.02	141,623	D
Common Stock	07/12/2018	S <u>(1)</u>	4,000	D	\$ 25.41 (2)	137,623	D
Common Stock	07/12/2018	M <u>(1)</u>	2,000	A	\$ 21.56	139,623	D
Common Stock	07/12/2018	S <u>(1)</u>	2,000	D	\$ 25.91 (3)	137,623	D
Common Stock	07/12/2018	S(1)	11,999	D	\$ 25.4 (4)	125,624	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Derivative Expiration Date ecurities (Month/Day/Year) Acquired (A) r Disposed of D) Instr. 3, 4,		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Stock Option(Right	\$ 13.26	07/12/2018		M(1)		11,000	02/22/2015	02/22/2021	Common Stock	11,

to Buy)								
Stock Option(Right to Buy)	\$ 15.44	07/12/2018	M <u>(1)</u>	5,500	02/14/2016	02/14/2022	Common Stock	5,5
Stock Option(Right to Buy)	\$ 12.58	07/12/2018	M <u>(1)</u>	6,000	02/19/2017	02/19/2023	Common Stock	6,0
Stock Option(Right to Buy)	\$ 17.96	07/12/2018	M <u>(1)</u>	6,000	02/18/2018	02/18/2024	Common Stock	6,0
Stock Option(Right to Buy)	\$ 13.02	07/12/2018	M <u>(1)</u>	4,000	05/18/2018	02/18/2025	Common Stock	4,0
Stock Option(Right	\$ 21.56	07/12/2018	M <u>(1)</u>	2,000	05/11/2018	08/11/2025	Common	2,0

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		

KWON YOUNG C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE, MA 02142

SVP, Corporate Development

Signatures

to Buy)

/s/ Alejandra Carvajal as attorney in fact 07/16/2018

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades at prices ranging from \$24.90 to \$25.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- This transaction was executed in multiple trades at prices ranging from \$25.90 to \$25.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- This transaction was executed in multiple trades at prices ranging from \$24.90 to \$25.90. The price reported above reflects the weighted (4) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 3

Edgar Filing: KWON YOUNG - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.